Trial Profile

Longterm Follow-up of Subjects Treated With bb2121

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idecabtagene vicleucel (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors bluebird bio; Celgene Corporation; Genetix Biotherapeutics

Most Recent Events

18 Sep 2025 According to Bluebird bio media release, Bluebird bio has changed its name to Genetix Biotherapeutics.
20 Jan 2020 Status changed from recruiting to completed.
30 Aug 2018 Planned End Date changed from 1 Apr 2035 to 28 Apr 2035.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com